{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:24:48Z","timestamp":1789770288268,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.atherosclerosis.2018.08.035","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T18:32:11Z","timestamp":1535394731000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Use of proton pump inhibitors and risk of ischemic events in the general population"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-5361","authenticated-orcid":false,"given":"Manuela","family":"Casula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-4150","authenticated-orcid":false,"given":"Federica","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mozzanica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-8444","authenticated-orcid":false,"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.08.035_bib1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinthera.2009.04.012","article-title":"Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing","volume":"31","author":"Barozzi","year":"2009","journal-title":"Clin. Therapeut."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.035_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009","volume":"8","author":"Rotman","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2018.08.035_bib3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1046\/j.1365-2036.2001.01128.x","article-title":"Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis","volume":"15","author":"Edwards","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2018.08.035_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.08.035_bib5","doi-asserted-by":"crossref","unstructured":"Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern. Med..49(23):2561-2568. PubMed PMID: 21139293. Epub 2010\/12\/09. eng.","DOI":"10.2169\/internalmedicine.49.4064"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.08.035_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.amjopharm.2008.12.001","article-title":"Appropriate proton pump inhibitor use among older adults: a retrospective chart review","volume":"6","author":"George","year":"2008","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2018.08.035_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejim.2016.01.025","article-title":"Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: attitudes of general practitioners and hospital physicians in Italy","volume":"30","author":"Lodato","year":"2016","journal-title":"Eur. J. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.08.035_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the american gastroenterological association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.08.035_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MJT.0b013e31817149bf","article-title":"Is there a dark side to long-term proton pump inhibitor therapy?","volume":"15","author":"Nealis","year":"2008","journal-title":"Am. J. Therapeut."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.035_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11938-017-0115-5","article-title":"Clinical implications of emerging data on the safety of proton pump inhibitors","volume":"15","author":"Schnoll-Sussman","year":"2017","journal-title":"Curr. Treat. Options Gastroenterol."},{"issue":"23","key":"10.1016\/j.atherosclerosis.2018.08.035_bib11","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.109.907295","article-title":"Proton pump inhibitors and clopidogrel: putting the interaction in perspective","volume":"120","author":"Juurlink","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.08.035_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2018.08.035_bib13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/gut.2008.148833","article-title":"Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial","volume":"57","author":"Lundell","year":"2008","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2018.08.035_bib14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cgh.2009.05.021","article-title":"Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis","volume":"7","author":"Lundell","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol. : The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.08.035_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","article-title":"Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study","volume":"153","author":"Charlot","year":"2010","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.035_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijcard.2014.09.036","article-title":"Proton pump inhibitor use represents an independent risk factor for myocardial infarction","volume":"177","author":"Shih","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.035_bib17","article-title":"Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis","volume":"29","author":"Sun","year":"2017","journal-title":"Neuro Gastroenterol. Motil.: Off. J. Eur. Gastrointes. Motility Soc."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.08.035_bib18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ajg.2017.101","article-title":"Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study","volume":"112","author":"Wang","year":"2017","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.035_bib19","first-page":"117","article-title":"Pharmacoepidemiological research and the linking of electronic healthcare databases available in the Italian region of Lombardy","volume":"2","author":"Corrao","year":"2008","journal-title":"BioMed. Stat. Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.08.035_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chron. Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.035_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut and liver"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.08.035_bib22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jgh.13737","article-title":"Proton pump inhibitors: risks of long-term use","volume":"32","author":"Eusebi","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.08.035_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1536\/ihj.16-208","article-title":"Potential cardiovascular risks of proton pump inhibitors in the general population","volume":"58","author":"Zhu","year":"2017","journal-title":"Int. Heart J."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.035_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2018.08.035_bib25","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin","volume":"4","author":"Gilard","year":"2006","journal-title":"J. Thromb. Haemostasis : JTH."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.08.035_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124653","article-title":"Proton pump inhibitor usage and the risk of myocardial infarction in the general population","volume":"10","author":"Shah","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.035_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.12698","article-title":"Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction","volume":"283","author":"Sehested","year":"2018","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.035_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/joim.12707","article-title":"Proton-pump inhibitor use and the risk of ischaemic stroke","volume":"283","author":"Dai","year":"2018","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.035_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40256-016-0160-9","article-title":"How may proton pump inhibitors impair cardiovascular Health?","volume":"16","author":"Sukhovershin","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs : Drugs, Devices, and Other Interventions"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.08.035_bib30","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2017.12.006","article-title":"No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indication","volume":"154","author":"Nguyen","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2018.08.035_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","article-title":"Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine","volume":"128","author":"Ghebremariam","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.035_bib32","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1038\/s41598-017-03069-1","article-title":"Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance","volume":"7","author":"Tommasi","year":"2017","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2018.08.035_bib33","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1161\/01.CIR.98.18.1842","article-title":"Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia","volume":"98","author":"Boger","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.08.035_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1358863X10364552","article-title":"Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease","volume":"15","author":"Wilson","year":"2010","journal-title":"Vasc. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.035_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12711","article-title":"Reply: proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population","volume":"283","author":"Sehested","year":"2018","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.035_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/ije\/dyx179","article-title":"Comparing methods to address bias in observational data: statin use and cardiovascular events in a US cohort","volume":"47","author":"Kaiser","year":"2018","journal-title":"Int. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.08.035_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2018.08.035_bib38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1592\/phco.30.10.985","article-title":"Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies","volume":"30","author":"Blackburn","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.08.035_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00228-014-1779-6","article-title":"Revising the link between proton-pump inhibitors and risk of acute myocardial infarction-a case-crossover analysis","volume":"71","author":"Turkiewicz","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.08.035_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MEG.0b013e328346a559","article-title":"Risk of acute myocardial infarction and stroke after discharge from in-hospital care due to complicated and uncomplicated peptic ulcer disease","volume":"23","author":"Sadr-Azodi","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2018.08.035_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084890","article-title":"Proton pump inhibitors and the risk of adverse cardiac events","volume":"8","author":"Juurlink","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.08.035_bib42","doi-asserted-by":"crossref","unstructured":"Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ.342:d2690. PubMed PMID: 21562004. Epub 2011\/05\/13. eng.","DOI":"10.1136\/bmj.d2690"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018313443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018313443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:52:51Z","timestamp":1558630371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018313443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"alternative-id":["S0021915018313443"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.035","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of proton pump inhibitors and risk of ischemic events in the general population","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}